Biology Reference
In-Depth Information
25. Aliakbar J, Sreedharan SP, Turck CW, Goetzl EJ. Selective localization of vasoactive
intestinal peptide and substance P in human eosinophils. Biochem Biophys Res Commun
1987;148:1440-45.
26. Ho W-Z, Lai J-P, Zhu X-H, Uvaydova M, Douglas SD. Human monocytes and mac-
rophages express substance P and neurokinin-1 receptor. J Immunol 1997;159:5654-60.
27. Lambrecht BN, Germonpre PR, Everaert EG, Carro-Muino I, De Veerman M, De Felipe C,
et al. Endogenously produced substance P contributes to lymphocyte proliferation induced
by dendritic cells and direct TCR ligation. Eur J Immunol 1999;29:3815-25.
28. Page NM, Bell NJ, Gardiner SM, Manyonda IT, Brayley KJ, Strange PG, et al.
Characterization of the endokinins: human tachykinins with cardiovascular activity. Proc
Natl Acad Sci USA 2003;100:6245-50.
29. Duffy RA, Hedrick JA, Randolph G, Morgan CA, Cohen-Williams ME, Vassileva G,
et al. Centrally administered hemokinin-1 (HK-1), a neurokinin NK1 receptor agonist,
produces substance P-like behavioral effects in mice and gerbils. Neuropharmacology
2003;45:242-50.
30. Maggi CA. Tachykinin receptors and airway pathophysiology. Eur Resp J 1993;6:735-42.
31. Maggi CA. The mammalian tachykinin receptors. Gen Pharmacol 1995;5:911-44.
32. Maggi CA. The troubled story of tachykinins and neurokinins. Trend Pharm Sci
2000;21:173-75.
33. Maggi CA, Patacchini R, Rovero P, Giachetti A. Tachykinin receptors and tachykinin
receptor antagonists. J Auton Pharmacol 1993;13:23-93.
34. Joos GF, De Swert KO, Pauwels RA. Airway inflammation and tachykinins: prospects
for the development of tachykinin receptor antagonists. Eur J Pharmacol 2001;429:
239-50.
35. Pinto FM, Almeida TA, Hernandez M, Devillier P, Advenier C, Candenas ML. mRNA
expression of tachykinins and tachykinin receptors in different human tissues. Eur J
Pharmacol 2004;494:233-39.
36. Mapp CE, Miotto D, Braccioni F, Saetta M, Turato G, Maestrelli P, et al. The distribution
of neurokinin-1 and neurokinin-2 receptors in human central airways. Am J Respir Crit
Care Med 2000;161:207-15.
37. Mechiche H, Koroglu A, Candenas L, Pinto FM, Birembaut P, Bardou M, et al.
Neurokinins induce relaxation of human pulmonary vessels through stimulation of
endothelial NK1 receptors. J Cardiovasc Pharmacol 2003;41:343-55.
38. Wiedermann CJ, Wieddermann FJ, Apperl A, Kieselbach G, Konwalinka G, Braunsteiner H.
In vitro
human polymorphonuclear leukocyte chemokinesis and human monocyte chemo-
taxis are different activities of aminoterminal and carboxyterminal substance P. Naunyn
Schmiedebergs Arch Pharmacol 1989;340:185-90.
39. Cooke HJ, Fox P, Alferes L, Fox CC, Wolfe SA. Presence of NK1 receptors on a mucosal-
like mast cell line, RBL-2H3 cells. Can J Physiol Pharmacol 1998;76:188-93.
40. Tanaka DT, Grunstein MM. Mechanisms of substance P-induced contraction of rabbit air-
way smooth muscle. J Appl Physiol 1984;57:1551-57.
41. Finney MJB, Karlsson JA, Persson CGA. Effects of bronchoconstrictors and bronchodila-
tors on a novel human small airway preparation. Br J Pharmacol 1985;85:29-36.
42. Advenier C, Joos G, Molimard M, Lagente V, Pauwels R. Role of tachykinins as contrac-
tile agonists of human airways in asthma. Clin Exp Allergy 1999;29:579-84.
43. Martling C-R, Theodorsson-Norheim E, Lundberg JM. Occurrence and effects of multiple
tachykinins; substance P, neurokinin A and neuropeptide K in human lower airways. Life
Sci 1987;40:1633-43.
44. Advenier C, Naline E, Drapeau G, Regoli D. Relative potencies of neurokinins in guinea-
pig trachea and human bronchus. Eur J Pharmacol 1987;139:133-37.
